

AD \_\_\_\_\_

GRANT NO: DAMD17-94-J-4183

TITLE: Developing a System for Directed Gene Introduction Into Mammary Gland Via Targeted Infection of Retrovirus Receptor Transgenics

PRINCIPAL INVESTIGATOR(S): Paul Bates, Ph.D.

CONTRACTING ORGANIZATION: University of Pennsylvania  
Philadelphia, Pennsylvania 19104-3246

REPORT DATE: September 1995

TYPE OF REPORT: Annual



PREPARED FOR: Commander  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19951124 050

DTIC QUALITY INSPECTED 1

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 1995		3. REPORT TYPE AND DATES COVERED Annual (9/1/94-8/31/95)
4. TITLE AND SUBTITLE Developing a System for Directed Gene Introduction Into Mammary Gland Via Targeted Infection of Retrovirus...				5. FUNDING NUMBERS DAMD17-94-J-4183
6. AUTHOR(S) Paul Bates, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pennsylvania Philadelphia, Pennsylvania 19104-3246				8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING/MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 words)  This work describes the development of a novel system for efficient and rapid introduction of genes into specific tissues or cells in mice i.e. <i>in vivo</i> targeted gene expression. Detailed analysis of gene function often relies upon introduction of genes into an animal model system. We are developing a retroviral-based system in which controlled expression of the cellular receptor for the virus in a defined pattern determines the site(s) of infection. Using this retroviral gene delivery system, a gene can be introduced not only in a spatial-specific pattern but also in a temporally-controlled manner. For these studies we will express the virus receptor in mammary cells in transgenic mice using a MMTV LTR. The ability to selectively target retroviral infection has numerous applications in areas as diverse as developmental biology, gene therapy and oncogenesis. Here we will attempt to utilize this system for targeted expression of genes in mammary cells in an animal model.				
14. SUBJECT TERMS breast cancer transgenic, animal model, retrovirus, tumorigenesis				15. NUMBER OF PAGES 8
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet optical scanning requirements.

**Block 1. Agency Use Only (Leave blank).**

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit Accession No.

**Block 6. Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es).** Self-explanatory.

**Block 8. Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es).** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number.** (If known)

**Block 11. Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.** Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."

DOE - See authorities.

NASA - See Handbook NHB 2200.2.

NTIS - Leave blank.

**Block 12b. Distribution Code.**

DOD - Leave blank.

DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

NASA - Leave blank.

NTIS - Leave blank.

**Block 13. Abstract.** Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms.** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages.** Enter the total number of pages.

**Block 16. Price Code.** Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19. Security Classifications.** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20. Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

PB In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

PB In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

PB In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Accession For	
NTIS GRA&I	<input checked="checked" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

UAB 10/2/95  
PI - Signature Date

## TABLE OF CONTENTS

<u>Section</u>	<u>page</u>
INTRODUCTION	1-2
BODY	2-3
CONCLUSIONS	3
REFERENCES	3-4

## INTRODUCTION

Presently, the most common way to analyze gene function in a particular cell type *in vivo* is to generate a new transgenic line for each gene under study - a costly and time consuming endeavor. Here we describe an approach which utilizes mice expressing a retroviral receptor transgene (the Rous sarcoma virus receptor) to target infection of retroviral vectors *in vivo*. This allows directed infection, and thus directed gene expression, of cells expressing the viral receptor and provides a rapid and efficient method to test the mammary tumorigenic potential of genes in an animal model. An important difference between this approach and testing gene function in transgenic mice is that infection, and thus gene expression, can be temporally controlled allowing assessment of differences in oncogenic potential at different stages of mammary gland development. Finally, multiple oncogenes can be introduced by co-infection, allowing questions of synergy to be addressed.

The goals of this proposal are: 1) characterize the expression Tva in the mammary gland and 2) optimize Tva-directed infection of mammary cells *in vivo* using vectors carrying histochemical marker genes. Importantly, we have already proven that targeted infection can be accomplished *in vivo*. Efficient infection of myoblasts by avian retroviral vectors was shown in transgenic mice expressing this receptor in muscle. We have also shown that this receptor functions to mediate infection of mammary epithelial cells in culture. Further, we have generated transgenic mice carrying the viral receptor under control of a mammary-specific promoter, the MMTV LTR. Thus, we are poised to continue development of this system for our studies of gene function and oncogene cooperation during mammary tumorigenesis.

### 1. Isolation and characterization of the subgroup A RSV receptor.

A gene transfer strategy was used to isolate a chicken gene encoding the subgroup A RSV receptor, *tva* [1, 2]. Mammalian cells are normally completely refractory to RSV-A infection. However, the *tva* gene renders mammalian cells as susceptible to RSV-A infection as avian cells [1, 2]. We have introduced the receptor gene into numerous different mammalian cell lines in species ranging from mouse to monkey, and in all cases Tva efficiently induces susceptibility to RSV-A. Taken together these results suggest that Tva can function to mediate efficient infection of many, if not all, mammalian cells.

### 2. Transgenic mice with $\alpha$ -actin promoter/*tva*: muscle specific receptor expression.

In collaboration with Steve Hughes at NCI we produced mice which carry RSV receptor transgenes (see attached PNAS paper,[3]). Using a muscle specific  $\alpha$ -actin promoter/*tva* construct, we established five mouse lines carrying this transgene. Characterization of these lines by Western blot analysis demonstrates that the receptor is specifically expressed in several types of muscle. Although the level and pattern of expression in muscle vary for each of the transgenic lines, these experiments demonstrate that in general, the receptor can efficiently expressed without deleterious effects. Furthermore, using mice carrying a  $\beta$ -actin promoter/*tva* construct we have demonstrated expression of Tva in numerous cell types including early embryonic cells further suggesting that expression of Tva in most contexts is not detrimental.

### 3. RSV infection of myoblasts *in vivo*

Preliminary infection studies have been performed with the  $\alpha$ -actin promoter/*tva* transgenic lines [3]. 2000-5000 infectious units of an RSV vector carrying the bacterial alkaline phosphatase gene (RCAS(A)-BAP) were injected IM into 5 day old

mice. At d5 there is significant myogenesis occurring such that the myoblasts, if susceptible to RSV-A, should be good targets for infection. Controls for the experiments included injection of a subgroup E RCAS-BAP vector which should not utilize the subgroup A receptor and injection of non transgenic littermates. As expected, infection was seen only when the subgroup A virus was injected into transgenic mice. Several hundred infected myoblasts or myotubes are spread throughout the muscle and infection did not seem to be localized at the injection site. Furthermore, by injecting avian cells expressing the RSV vectors rather than the virus stock, infection of the myoblasts was dramatically increased such that thousands of cells appear to be infected. These experiments provide proof of principal for the use of Tva to efficiently target cells for RSV-A infection *in vivo*.

## BODY

In our statement of work for this project as task 1 we propose to construct a transgene which will give expression of the RSV viral receptor in mammary cells and generate transgenic mice carrying this gene. We have accomplished this task. Two of the goals of task 3 have also been addressed. We have constructed the retroviral vectors with histochemical markers required for testing targeting *in vivo*. Finally, preliminary infection experiments with these vectors have been initiated.

### **A. Expression of Tva in a mammary epithelial cell line allows RSV infection.**

Although we have demonstrated that Tva functions in a number of cultured cells and can infect muscle cells *in vivo* we wanted to test whether mammary epithelial cells would utilize the receptor to allow RSV entry. To address this question, and to determine if the plasmid to be used as the transgene was functional, an MMTV LTR/*tva* construct was introduced into a cultured mammary epithelial cell line, C57MG. The transfected cells were then challenged with an RSV vector carrying a  $\beta$ -galactosidase marker. Expression of the receptor renders C57MG cells highly susceptible to RSV infection as judged by  $\beta$ -gal staining. These experiments demonstrate that at least in cultured mammary cells there is no block to RSV infection if the receptor is expressed, and they suggest that *in vivo* RSV vectors should infect the mammary epithelial cells of MMTV LTR/*tva* transgenics.

### **B. Generation of mice with an MMTV LTR/RSV receptor transgene.**

The expression pattern of the MMTV LTR in mice has been thoroughly characterized. MMTV LTR constructs have been used extensively to construct transgenic mice for the purpose of expressing genes in the mammary gland [4-8]. Abundant expression in mammary epithelial cells is seen when this promoter is utilized. In addition to mammary gland expression, the MMTV LTR also promotes relatively high levels of expression of transgenes in the salivary gland and the testis. Indeed, in transgenics in which an oncogene is driven by this LTR both mammary and, less frequently, salivary gland tumors are induced. For these experiments, we used a construct with the MMTV LTR in the same orientation immediately upstream of the RSV receptor processed gene. Based on previous studies using an identical arrangement of the LTR and transgene this construct should promote high levels of receptor expression.

Two transgenic lines of mice carrying the MMTV/*tva* transgene have been established. Presently, in addition to the infection experiments which form the heart of this short proposal, we are breeding these mice into a C57/B6 background. Unfortunately, the particular cross used to produce the transgenic mice at the University of Pennsylvania transgenic facility has a high spontaneous mammary tumor rate.

Therefore, in preparation for use of these mice in future tumorigenesis studies, we are breeding into a C57/B6 background. The C57/B6 line of mice has a low spontaneous mammary tumor incidence. After the B1/6 background is established (5-6 generations of backcrossing), then mice homozygous for the transgene will be produced (assuming the transgene does not disrupt an essential gene). Producing homozygotes will simplify maintenance of the lines and obviate the need to screen mice for the transgene before conducting expression or infection experiments.

### **C. Virus vectors and stocks**

MLV(RSV) psuedotypes have been produced using a transient transfection protocol similar to one previously utilized to generate high titer MLV psuedotypes [9-12]. Using human 293T cells and a transient transfection protocol we routinely obtain titers of MLV(RSV) psuedotypes of roughly  $10^5$  infectious units/ml. Presently, we are optimizing a virus concentration protocol for RSV-A which allows 100-fold concentration of virus stock [13, 14]. We have constructed vectors which express either alkaline phosphatase or a nuclear localized lacZ for use in these studies. This transient virus expression system should allow rapid production of high titer MLV(RSV) vector stocks for use in the infection studies. As a control, we also will use subgroup C RSV psuedotypes. Viruses with this envelope do not use the subgroup A receptor and should not infect the transgenic mice. Positive controls will include viruses carrying the MLV envelope protein and VSV G glycoprotein [12-14]. Having these viruses in hand we are now ready to begin testing the in vivo targeting of mammary epithelial cells.

### **D. Infection of mammary gland cells *in vivo* and primary cultures *in vitro*.**

In preliminary injection experiments we have not yet seen evidence for infection by the RSV psuedotypes. Therefore, while proceeding with the in vivo infections, experiments on explanted primary mammary cells from the transgenic mice will be initiated. Although not in the original plan, these experiments will help clarify if the problems encountered thus far with the infections are technical (due to our technique used for the infections) or biological (that the transgene is not conferring susceptibility as expected). The primary cell cultures will allow us to easily address this question. Also, we can analyze the expression of the receptor protein much more easily in the cultured cells, checking not only for the presence of the receptor but also assaying whether it localizes to the cell surface.

## **CONCLUSIONS**

Although this project is still in its early stages we have made significant progress this year. We have made the transgene constructs, used them to produce and establish two lines carrying the MMTV LTR/RSV transgene, produced virus vectors required for this project and established protocols for production of high titer stocks of viruses carrying these vectors, and finally begun preliminary infection experiments. From this work we can conclude that the transgene is not toxic in vivo and mice can be produced. Also we now know that the RSV psuedotype system will allow rapid and efficient production of virus stocks carrying MLV genomes. This will allow us to utilize the many oncogene constructs already in MLV vectors for our future work on this project.

## **REFERENCES**

1. Bates, P., J. Young, A.T., and H. Varmus, E., *A receptor for subgroup-A Rous sarcoma virus is related to the low-density-lipoprotein receptor*. Cell, 1993. **74**(6): p. 1043-1051.

2. Young, J.A.T., P. Bates, and H.E. Varmus, *Isolation of a chicken gene that confers susceptibility to infection by subgroup A avian leukosis and sarcoma viruses*. J Virol, 1993. **67**(4): p. 1811-6.
3. Federspiel, M.J., et al., *A system for tissue-specific gene targeting: transgenic mice susceptible to subgroup-a avian-leukosis virus-based retroviral vectors*. Proceedings Of The National Academy Of Sciences Of The United States Of America, 1994. **91**(23): p. 11241-11245.
4. Manges, R., et al., *Tumorigenesis and male sterility in transgenic mice expressing a MMTV/N-ras oncogene*. Oncogene, 1990. **5**(10): p. 1491-7.
5. Muller, W.J., et al., *Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene*. Cell, 1988. **54**(1): p. 105-15.
6. Muller, W.J., et al., *The int-2 gene product acts as an epithelial growth factor in transgenic mice*. EMBO Journal, 1990. **9**(3): p. 907-13.
7. Tsukamoto, A.S., et al., *Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice*. Cell, 1988. **55**(4): p. 619-25.
8. Bouchard, L., et al., *Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene*. Cell, 1989. **57**(6): p. 931-6.
9. Landau, N.R. and D.R. Littman, *Packaging system for rapid production of murine leukemia virus vectors with variable tropism*. J Virol, 1992. **66**(8): p. 5110-3.
10. Soneoka, Y., et al., *A transient three-plasmid expression system for the production of high titer retroviral vectors*. Nucleic Acids Research, 1995. **23**(4): p. 628-33.
11. Yee, J.K., et al., *A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes*. Proceedings of the National Academy of Sciences of the United States of America, 1994. **91**(20): p. 9564-8.
12. Yee, J.K., T. Friedmann, and J.C. Burns, *Generation of high-titer pseudotyped retroviral vectors with very broad host range*. Methods in Cell Biology, 1994. **43**(Pt A): p. 99-112.
13. Burns, J.C., et al., *Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells [see comments]*. Proceedings of the National Academy of Sciences of the United States of America, 1993. **90**(17): p. 8033-7.
14. Burns, J.C., et al., *Pantropic retroviral vector-mediated gene transfer, integration, and expression in cultured newt limb cells*. Developmental Biology, 1994. **165**(1): p. 285-9.